Financial News
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
3,805 articles
Is BrightSpring BTSG Stock Expensive at 24.5x Forward P/E?
BTSG trades at 24.5x forward earnings after strong 2025 results, but 2026 hinges on margin gains offsetting policy-driven revenue headwinds.
Is BrightSpring BTSG Stock Expensive at 24.5x Forward P/E?
BTSG trades at 24.5x forward earnings after strong 2025 results, but 2026 hinges on margin gains offsetting policy-driven revenue headwinds.
BTSG and the Shift to Home Care as Margins Expand in 2026
BTSG targets margin expansion in 2026 as home-care demand grows, but policy and pricing pressures could cloud revenue trends.
BTSG and the Shift to Home Care as Margins Expand in 2026
BTSG targets margin expansion in 2026 as home-care demand grows, but policy and pricing pressures could cloud revenue trends.
Is BrightSpring BTSG Stock Expensive at 24.5x Forward P/E?
BTSG trades at 24.5x forward earnings after strong 2025 results, but 2026 hinges on margin gains offsetting policy-driven revenue headwinds.
Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?
Bristol Myers Squibb's Opdivo expansions highlight pharma companies' push to grow oncology franchises amid rising competition and pipeline innovation.
Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?
Bristol Myers Squibb's Opdivo expansions highlight pharma companies' push to grow oncology franchises amid rising competition and pipeline innovation.
BTSG Growth Drivers in 2026 Across Specialty and Providers
BTSG leans on specialty and provider growth in 2026, with margin expansion expected to outpace revenue despite near-term pharmacy headwinds.
Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?
Bristol Myers Squibb's Opdivo expansions highlight pharma companies' push to grow oncology franchises amid rising competition and pipeline innovation.
BTSG Growth Drivers in 2026 Across Specialty and Providers
BTSG leans on specialty and provider growth in 2026, with margin expansion expected to outpace revenue despite near-term pharmacy headwinds.
BTSG Growth Drivers in 2026 Across Specialty and Providers
BTSG leans on specialty and provider growth in 2026, with margin expansion expected to outpace revenue despite near-term pharmacy headwinds.
📰
Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today
AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.51% on an annualized basis producing an average annual return of 13.85%....
📰
Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should Know
Coherus Oncology (CHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might...
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?
Regeneron's rally reflects biotech momentum as pipeline wins and Dupixent growth offset Eylea erosion amid intensifying competition.
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?
Regeneron's rally reflects biotech momentum as pipeline wins and Dupixent growth offset Eylea erosion amid intensifying competition.
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?
Regeneron's rally reflects biotech momentum as pipeline wins and Dupixent growth offset Eylea erosion amid intensifying competition.
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?
Regeneron's rally reflects biotech momentum as pipeline wins and Dupixent growth offset Eylea erosion amid intensifying competition.
Reasons Behind Holding Humana Shares: What Investors Need to Know
HUM's value-based care model, Medicare Advantage growth and CenterWell expansion drive momentum despite cost pressures and a 36% stock decline.
Reasons Behind Holding Humana Shares: What Investors Need to Know
HUM's value-based care model, Medicare Advantage growth and CenterWell expansion drive momentum despite cost pressures and a 36% stock decline.
Reasons Behind Holding Humana Shares: What Investors Need to Know
HUM's value-based care model, Medicare Advantage growth and CenterWell expansion drive momentum despite cost pressures and a 36% stock decline.
Reasons Behind Holding Humana Shares: What Investors Need to Know
HUM's value-based care model, Medicare Advantage growth and CenterWell expansion drive momentum despite cost pressures and a 36% stock decline.
AQST INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics Investors of Securities Class Action Deadline on May 4, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him...
BSX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Boston Scientific To Contact...
📰
Myriad (MYGN) Up 4.1% Since Last Earnings Report: Can It Continue?
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
📰
Myriad (MYGN) Up 4.1% Since Last Earnings Report: Can It Continue?
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
📰
Why Is ImmunityBio (IBRX) Down 35.8% Since Last Earnings Report?
ImmunityBio (IBRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
📰
Why Is Hims & Hers Health (HIMS) Up 38% Since Last Earnings Report?
Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
📰
Why Is ImmunityBio (IBRX) Down 35.8% Since Last Earnings Report?
ImmunityBio (IBRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
📰
Why Is Hims & Hers Health (HIMS) Up 38% Since Last Earnings Report?
Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
📰
BioMarin (BMRN) Down 13.6% Since Last Earnings Report: Can It Rebound?
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
📰
BioMarin (BMRN) Down 13.6% Since Last Earnings Report: Can It Rebound?
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
📰
Why Is Axsome (AXSM) Down 6.6% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst
Merck & Co Inc. (NYSE:MRK) on Wednesday agreed to acquire Terns Pharmaceuticals Inc. (NASDAQ:TERN), as the U.S. drugmaker accelerates efforts to...
Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst
Merck & Co Inc. (NYSE:MRK) on Wednesday agreed to acquire Terns Pharmaceuticals Inc. (NASDAQ:TERN), as the U.S. drugmaker accelerates efforts to...
Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst
Merck & Co Inc. (NYSE:MRK) on Wednesday agreed to acquire Terns Pharmaceuticals Inc. (NASDAQ:TERN), as the U.S. drugmaker accelerates efforts to...
Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst
Merck & Co Inc. (NYSE:MRK) on Wednesday agreed to acquire Terns Pharmaceuticals Inc. (NASDAQ:TERN), as the U.S. drugmaker accelerates efforts to...
Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst
Merck & Co Inc. (NYSE:MRK) on Wednesday agreed to acquire Terns Pharmaceuticals Inc. (NASDAQ:TERN), as the U.S. drugmaker accelerates efforts to...
LivaNova Expands OSA Care With FDA-Approved aura6000 System
LIVN wins FDA nod for its aura6000 sleep apnea system, marking a pivotal step in neurostimulation with strong trial results and new growth potential.
LivaNova Expands OSA Care With FDA-Approved aura6000 System
LIVN wins FDA nod for its aura6000 sleep apnea system, marking a pivotal step in neurostimulation with strong trial results and new growth potential.
LivaNova Expands OSA Care With FDA-Approved aura6000 System
LIVN wins FDA nod for its aura6000 sleep apnea system, marking a pivotal step in neurostimulation with strong trial results and new growth potential.
LivaNova Expands OSA Care With FDA-Approved aura6000 System
LIVN wins FDA nod for its aura6000 sleep apnea system, marking a pivotal step in neurostimulation with strong trial results and new growth potential.
Why Is Sarepta Therapeutics Stock Exploding Today?
Sarepta Therapeutics Inc. (NASDAQ:SRPT) shares are up on Wednesday following the announcement of promising clinical results from its siRNA programs...
📰
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading
European equities traded in the US as American depositary receipts were tracking higher late Wednesd
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
FMS eyes growth on value-based care surge and FME25+ savings, but regulatory headwinds, flat volumes and China weakness cloud outlook.
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
FMS eyes growth on value-based care surge and FME25+ savings, but regulatory headwinds, flat volumes and China weakness cloud outlook.